Pharmaceuticals company Aurobindo Pharma announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 91,503.5 million, representing a YoY growth of 16.3% compared to Rs 78,681.4 million in Q1FY26 and a QoQ increase of 3.35% from Rs 88,533.4 million in Q4FY26. Total Income: Reached Rs 94,145.8 million, up 18.08% YoY from Rs 79,734.4 million and up 4.95% QoQ from Rs 89,703.8 million. Profit Before Tax (PBT): Reported at Rs 15,150.9 million, an increase of 25.55% YoY from Rs 12,068.0 million and a growth of 17.4% QoQ from Rs 12,906.1 million. Profit After Tax (PAT): Net profit attributable to owners of the parent company was Rs 10,325.6 million, marking a YoY growth of 25.2% from Rs 8,247.5 million and a QoQ growth of 12.08% from Rs 9,212.6 million. Earnings Per Share (EPS): Basic and diluted EPS stood at Rs 17.86 for the quarter, compared to Rs 14.20 in Q1FY26 and Rs 15.86 in Q4FY26. Standalone Financial Highlights: Revenue from Operations: Stood at Rs 27,995.1 million, reflecting a YoY decline of 1.71% from Rs 28,481.7 million, but a marginal QoQ increase of 0.47% from Rs 27,865.5 million in Q4FY26. Total Income: Reached Rs 30,414.0 million, up 3.73% YoY from Rs 29,319.4 million and up 1.36% QoQ from Rs 30,006.4 million. Profit Before Tax (PBT): Reported at Rs 10,080.8 million, an increase of 34.39% YoY from Rs 7,500.9 million and a growth of 15.04% QoQ from Rs 8,763.1 million. Profit After Tax (PAT): Net profit for the quarter was Rs 7,372.2 million, up 31.85% YoY from Rs 5,591.3 million and up 6.5% QoQ from Rs 6,922.3 million. Business Highlights: US Revenue: Increased by 8.1% YoY to Rs 37,700 million, primarily driven by volume gains and new launches, and grew 6.4% QoQ from Rs 35,430 million. Europe Revenue: Grew significantly by 25.6% YoY to Rs 29,370 million, accounting for 32.1% of consolidated revenue, and grew 5.1% QoQ from Rs 27,950 million. Growth Markets Revenue: Saw a robust growth of 37.7% YoY to Rs 10,630 million and an 8.5% QoQ increase from Rs 9,800 million. ARV Revenue: Stood at Rs 3,300 million, a YoY decrease of 6.9% but a marginal QoQ increase of 0.8% compared to Q4FY26. Active Pharmaceutical Ingredients (API) Revenue: Grew by 14.6% YoY to Rs 10,490 million, although it saw a sequential QoQ decline of 13.1% from Rs 12,080 million due to seasonal softness in the antibiotics portfolio. Acquisitions & Buyback: The company completed the acquisition of 100% membership interest in Lannett Company LLC on June 29, 2026. Additionally, the company approved a buyback of equity shares for an aggregate value not exceeding Rs 8,000 million. Product Approvals: Received final approval for 10 products from USFDA during the quarter. Cash Flow: Generated free cash flow of USD 98 million during the quarter. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company, said: “We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders.” Result PDF